Literature DB >> 31911557

The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.

Eman Sami1, Bibbin T Paul2, James A Koziol3, Wael M ElShamy4.   

Abstract

Tumor-associated macrophages (TAM) promote triple-negative breast cancer (TNBC) progression. Here, we report BRCA1-IRIS-overexpressing (IRISOE) TNBC cells secrete high levels of GM-CSF in a hypoxia-inducible factor-1α (HIF1α)- and a NF-κB-dependent manner to recruit macrophages to IRISOE cells and polarize them to protumor M2 TAMs. GM-CSF triggered TGFβ1 expression by M2 TAMs by activating STAT5, NF-κB, and/or ERK signaling. Despite expressing high levels of TGFβ1 receptors on their surface, IRISOE TNBC cells channeled TGFβ1/TβRI/II signaling toward AKT, not SMAD, which activated stemness/EMT phenotypes. In orthotopic and syngeneic mouse models, silencing or inactivating IRIS in TNBC cells lowered the levels of circulating GM-CSF, suppressed TAM recruitment, and decreased the levels of circulating TGFβ1. Coinjecting macrophages with IRISOE TNBC cells induced earlier metastasis in athymic mice accompanied by high levels of circulating GM-CSF and TGFβ1. IRISOE TNBC cells expressed low levels of calreticulin (the "eat me" signal for macrophages) and high levels of CD47 (the "do not eat me" signal for macrophages) and PD-L1 (a T-cell inactivator) on their surface. Accordingly, IRISOE TNBC tumors had significantly few CD8+/PD-1+ cytotoxic T cells and more CD25+/FOXP3+ regulatory T cells. These data show that the bidirectional interaction between IRISOE cells and macrophages triggers an immunosuppressive microenvironment within TNBC tumors that is favorable for the generation of immune-evading/stem-like/IRISOE TNBC metastatic precursors. Inhibiting this interaction may inhibit disease progression and enhance patients' overall survival. SIGNIFICANCE: The BRCA1-IRIS oncogene promotes breast cancer aggressiveness by recruiting macrophages and promoting their M2 polarization. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31911557      PMCID: PMC7056552          DOI: 10.1158/0008-5472.CAN-19-2374

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF.

Authors:  Daniela F Quail; Oakley C Olson; Priya Bhardwaj; Logan A Walsh; Leila Akkari; Marsha L Quick; I-Chun Chen; Nils Wendel; Nir Ben-Chetrit; Jeanne Walker; Peter R Holt; Andrew J Dannenberg; Johanna A Joyce
Journal:  Nat Cell Biol       Date:  2017-07-24       Impact factor: 28.824

2.  Purification and properties of colony-stimulating factor from mouse lung-conditioned medium.

Authors:  A W Burgess; J Camakaris; D Metcalf
Journal:  J Biol Chem       Date:  1977-03-25       Impact factor: 5.157

3.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

Authors:  Hazem Ghebeh; Shamayel Mohammed; Abeer Al-Omair; Amal Qattan; Cynthia Lehe; Ghofran Al-Qudaihi; Naser Elkum; Mohamed Alshabanah; Suad Bin Amer; Asma Tulbah; Dahish Ajarim; Taher Al-Tweigeri; Said Dermime
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

4.  TGF-beta suppresses EGF-induced MAPK signaling and proliferation in asthmatic epithelial cells.

Authors:  Abdelhabib Semlali; Eric Jacques; Sophie Plante; Sabrina Biardel; Julie Milot; Michel Laviolette; Louis-Philippe Boulet; Jamila Chakir
Journal:  Am J Respir Cell Mol Biol       Date:  2007-09-13       Impact factor: 6.914

Review 5.  Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Authors:  Stefano Ugel; Francesco De Sanctis; Susanna Mandruzzato; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

6.  Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1.

Authors:  Christopher A Pettigrew; Juliet D French; Jodi M Saunus; Stacey L Edwards; Aisha V Sauer; Chanel E Smart; Therese Lundström; Christiane Wiesner; Amanda B Spurdle; Joseph A Rothnagel; Melissa A Brown
Journal:  Breast Cancer Res Treat       Date:  2008-12-09       Impact factor: 4.872

7.  BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.

Authors:  Abhilasha Sinha; Bibbin T Paul; Lisa M Sullivan; Hillary Sims; Ahmed El Bastawisy; Hend F Yousef; Abdel-Rahman N Zekri; Abeer A Bahnassy; Wael M ElShamy
Journal:  Oncotarget       Date:  2017-02-07

8.  GM-CSF promotes a supportive adipose and lung microenvironment in metastatic breast cancer.

Authors:  Francesca Reggiani; Francesco Bertolini
Journal:  Oncoscience       Date:  2017-10-23

9.  BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation.

Authors:  Andrew G Li; Elizabeth C Murphy; Aedin C Culhane; Emily Powell; Hua Wang; Roderick T Bronson; Thanh Von; Anita Giobbie-Hurder; Rebecca S Gelman; Kimberly J Briggs; Helen Piwnica-Worms; Jean J Zhao; Andrew L Kung; William G Kaelin; David M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-25       Impact factor: 11.205

10.  Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer.

Authors:  Zhaoxu Fang; Chengwen Wen; Xiaolan Chen; Rongping Yin; Chenglin Zhang; Xiaohua Wang; Yuhui Huang
Journal:  Oncotarget       Date:  2017-04-10
View more
  17 in total

1.  Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.

Authors:  Patricia Castillo; Omonigho Aisagbonhi; Cheryl C Saenz; Wael M ElShamy
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

2.  Mapping the Tumor Microenvironment in TNBC and Deep Exploration for M1 Macrophages-Associated Prognostic Genes.

Authors:  Baojin Xu; Hefen Sun; Xiaoqing Song; Qiqi Liu; Wei Jin
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

3.  Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer.

Authors:  He Zhang; Guohui Qin; Hui Yu; Xu Han; Sha Zhu
Journal:  Cancer Immunol Immunother       Date:  2020-12-10       Impact factor: 6.968

4.  CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression.

Authors:  Meiling Zhang; Zongzhi Z Liu; Keisuke Aoshima; Wesley L Cai; Hongyin Sun; Tianrui Xu; Yangyi Zhang; Yongyan An; Jocelyn F Chen; Lok Hei Chan; Asako Aoshima; Sabine M Lang; Zhenwei Tang; Xuanlin Che; Yao Li; Sara J Rutter; Veerle Bossuyt; Xiang Chen; Jon S Morrow; Lajos Pusztai; David L Rimm; Mingzhu Yin; Qin Yan
Journal:  Sci Transl Med       Date:  2022-02-02       Impact factor: 19.319

Review 5.  The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.

Authors:  Yiqi Fan; Shuai He
Journal:  Cancer Manag Res       Date:  2022-01-03       Impact factor: 3.989

6.  STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment.

Authors:  Emily A Jesser; Nicholas J Brady; Danielle N Huggins; Patrice M Witschen; Christine H O'Connor; Kathryn L Schwertfeger
Journal:  Breast Cancer Res       Date:  2021-11-07       Impact factor: 6.466

Review 7.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Michela Sebastiano; Veronica Zelli; Stefano Guadagni; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2020-06-15

8.  Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.

Authors:  Mohammed Moustapha Anwar; Manal Shalaby; Amira M Embaby; Hesham Saeed; Mona M Agwa; Ahmed Hussein
Journal:  Sci Rep       Date:  2020-09-07       Impact factor: 4.379

Review 9.  The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.

Authors:  Alberto Cruz-Bermúdez; Raquel Laza-Briviesca; Marta Casarrubios; Belén Sierra-Rodero; Mariano Provencio
Journal:  Biomedicines       Date:  2021-03-31

Review 10.  Crosstalk between Tumor Cells and Immune System Leads to Epithelial-Mesenchymal Transition Induction and Breast Cancer Progression.

Authors:  Raheleh Moradpoor; Mona Salimi
Journal:  Iran Biomed J       Date:  2020-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.